Clinical trial NCT04095819: Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)
Official title: Pilot Study to Evaluate Safety of and Efficacy of Middle Meningeal Artery (MMA) Embolization Compared to Traditional Surgical Strategies to Treat Chronic Subdural Hematomas (cSDH)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Subdural Hematoma
Lead sponsor: Atlantic Health System
Sponsor class: OTHER
First posted: 2019-09-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic Subdural Hematoma (cSDH) is a common hematologic problem particularly in older patients. The purpose of this study is to evaluate the safety and efficacy of middle meningeal artery (MMA) embolization compared to traditional surgical strategies for patients presenting with chronic subdural hematoma (cSDH). Although MMA embolization is minimally-invasive procedure that is routinely used for the treatment of tumors or vascular formations (1), this study investigates the use of an established procedure for a new disease state.

Detailed description: The purpose of the research study is to evaluate the safety and efficacy of a new, less-invasive procedure to treat chronic subdural hematoma (cSDH). A subdural hematoma occurs when blood collects on the brain's surface beneath the skull. Subdural hematomas can be life-threatening. They usually result from a head injury. This study will compare the new procedure to conventional surgical treatment of chronic subdural hematoma (cSDH). The new procedure is called middle meningeal artery embolization (MMA).

Current or conventional treatment of chronic subdural hematoma (cSDH) involves surgery (burr hole drainage and craniotomy) to access and remove the cause of the bleeding that is causing the subdural hematoma.

The new procedure, MMA embolization, involves guiding a catheter that is inserted into a blood vessel to the area of the brain that is supplying blood to the subdural hematoma. Particles or a special type of glue will be released to stop the bleeding that is causing the subdural hematoma. This technique has been used to treat other brain conditions, for example, (to treat tumors or malformation of blood vessels).

Eligibility criteria: Inclusion Criteria:

* Age 18 or older
* Participant or Surrogate must be English speaking
* Subjects must have a diagnosis of chronic or acute-on subdural hematoma based on brain imaging, as documented by an
* One or more symptoms attributable to chronic SDH including headache cognitive impairment, gait instability, seizure, or mild focal neurologic deficit.
* In opinion of Investigator or the subject's referring physician, the subject has failed conservative management.

Exclusion Criteria:

* The Subdural hematoma is causing mass effect significant enough to cause marked or progressive neurologic impairment
* Any requirement for urgent surgical evacuation is necessary
* Life expectancy is less than 6 months in the opinion of the subject's primary physician
* Markedly tortuous vasculature precluding safe endovascular access, as assessed on angiogram
* Acute subdural hematomas
* Health insurance doesn't cover MMA embolization or performing Surgeon and follow up visits are considered out of network.
* Pregnancy

Primary outcomes:
measure: Change in size of SDH
timeFrame: 6 months
Secondary outcomes:
measure: Change in Neurological status
timeFrame: 6 months
Other outcomes:
Locations:
city: Summit
country: United States
facility: Overlook Medical Center
state: New Jersey
Study officials:
References:
citation: Fuentes AM, Khalid SI, Mehta AI. Predictors of Subsequent Intervention After Middle Meningeal Artery Embolization for Treatment of Subdural Hematoma: A Nationwide Analysis. Neurosurgery. 2023 Jan 1;92(1):144-149. doi: 10.1227/neu.0000000000002151. Epub 2022 Sep 21.